Chiropractic Integrative Treatment Effectiveness for Migraines

Find out about integrative treatment methods that can enhance wellness and reduce migraine frequency with chiropractic care.

Abstract

Migraine is a complex neurological disorder that affects more than a billion people worldwide and profoundly impacts function, family life, and work. In this educational post, I share a comprehensive, first-person journey through the modern, evidence-based understanding of migraine—from accurate diagnosis and red-flag screening to the physiological underpinnings in the brain, brainstem, and trigeminovascular system. I explain why migraine is fundamentally a sensory processing disorder with central origins (hypothalamus, limbic connections, trigeminal nucleus caudalis), how neuropeptides like the calcitonin gene-related peptide (CGRP) drive neurogenic inflammation and pain, and how serotonin (5-HT) modulates this process. I present the latest therapeutic advances, including CGRP antagonists (monoclonal antibodies and gepants), 5-HT1F agonists (ditans), triptans, dihydroergotamine, and onabotulinumtoxinA for chronic migraine—explaining mechanisms, indications, contraindications, and practical use.
I also outline our multidisciplinary, patient-centered model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I collaborate with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), who brings over 40 years of experience. Together, we integrate chiropractic care, functional medicine, medical oversight, rehabilitation, and personal injury care to address biomechanical triggers, autonomic dysregulation, neuroinflammation, and central sensitization. I show how integrative chiropractic care fits into this modern treatment approach, detailing cervical-trigeminal convergence, segmental biomechanics, soft-tissue normalization, neuromotor retraining, vestibulo-oculomotor rehabilitation, and autonomic balancing—linked directly to migraine physiology.
You will leave with a clear framework for building an individualized plan: a stratified acute toolkit matched to attack phenotype; preventive strategies tailored to comorbidities and patient goals; integrative chiropractic and functional medicine supports; and safety monitoring for drug interactions and emerging postmarketing signals. This is a practical, well-developed, and hopeful roadmap for patients and clinicians who want to reduce migraine frequency, intensity, and duration; restore function; and reclaim life.

Meet Our Multidisciplinary Team and Clinical Philosophy

As a clinician who holds credentials as a Doctor of Chiropractic (DC) and Advanced Practice Registered Nurse (APRN), board-certified as a Family Nurse Practitioner (FNP-BC), with advanced training in functional and integrative medicine (CFMP, IFMCP) and sports and regenerative medicine (ATN, CCST), I approach migraine through multiple lenses—structural, neurological, biochemical, and behavioral. Our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, is structured as a multidisciplinary, integrative care center—a common and effective setup for complex conditions.

Our Collaborative Model: Internal Medicine + Chiropractic + Functional Medicine

• Medical Director and Collaborative Physician:
  • Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine
  • NPI #1164426749; Texas MD License #J2933
  • Over 40 years of experience as an internist
  • Provides medical direction, diagnostic oversight, risk stratification, and pharmacologic management
• Integrative Chiropractic and Functional Medicine:
  • Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST
  • Leads chiropractic structural care, neuromotor rehabilitation, and functional medicine
  • Focuses on cervical-trigeminal convergence, biomechanics, soft-tissue normalization, autonomic balancing, and upstream root causes
• Practice Services:
  • Internal medicine diagnostic evaluation and pharmacotherapy
  • Chiropractic adjustments, spinal decompression, cranial mobilization
  • Functional medicine protocols: nutrition, sleep, hormones, nutrient repletion
  • Rehabilitation: neuromuscular re-education, graded activity, vestibulo-oculomotor therapy
  • Personal injury care: whiplash, post-traumatic headache, concussion-related dysfunction

Why This Team-Based Model Works for Migraine

Migraine is not just head pain. It is an episodic neurological storm that scales across systems. In practice, pharmacotherapy addresses acute and preventive needs, but ignoring the cervical and autonomic drivers leaves patients vulnerable to recurrence and chronification. Our model unifies:

• Medical oversight to rule out secondary causes, manage comorbidities, and select safe/effective therapies.
• Chiropractic care to reduce cervical afferent bombardment into the trigeminal nucleus caudalis, improving sensorimotor function and reducing brainstem sensitization.
• Functional medicine to stabilize sleep, hormones, and metabolic terrain; quell systemic inflammation; and support mitochondrial energy.

Together, these threads create a cohesive, patient-centered plan that treats both the migraine generator and the terrain it thrives in.
For my ongoing clinical observations and professional insights:

• Clinical portal: https://chiromed.com/
• Professional profile: https://www.linkedin.com/in/dralexjimenez/

Understanding Migraine: Prevalence, Impact, and Why Primary Care Matters

The Widespread Impact of Migraine

• More than a billion people worldwide live with migraine.
• In the U.S., approximately one in five women and one in sixteen men are affected.
• One in eleven children experiences migraine; before puberty, prevalence is similar in boys and girls.
• In the U.S., one in four households has at least one member with migraine.

These numbers have practical meaning. In any busy clinic, multiple patients are struggling with migraine or migraine-like headaches daily. The disability is substantial—attacks can occupy three to four days when you account for prodrome, headache, and postdrome.

Who Manages Migraines? The Reality of Primary Care

Approximately 70% of people with migraine are managed in primary care. That reality places the responsibility on clinicians like me—chiropractors embedded in integrative practices, nurse practitioners, and family physicians—to diagnose accurately, screen vigilantly, and use modern therapies proficiently. The old model of suggesting rest and over-the-counter analgesics is not enough. Our toolkit has expanded, and our understanding has matured.

Accurate Diagnosis: Differentiating Migraine from Other Headaches

Accurate diagnosis is foundational. Migraine is variable and can be misread as sinus or tension-type headache. The priority is ruling out dangerous secondary headaches. Then we match clinical features to established criteria.

Red Flags: The SNOOP Mnemonic

Before diagnosing a primary headache, I systematically screen for secondary causes using SNOOP:

• S — Systemic symptoms: Fever, myalgias, weight loss may signal infection, inflammatory disease, or malignancy. I consider meningitis and other meningeal processes when systemic illness accompanies severe headache.
• N — Neurologic signs or symptoms: Focal deficits, confusion, seizures, or papilledema on fundoscopic exam point to raised intracranial pressure or structural lesions. These warrant urgent neuroimaging and possible emergency referral.
• O — Onset: A thunderclap headache (sudden maximal intensity in minutes) is a neurologic emergency—classically subarachnoid hemorrhage—and demands immediate action.
• O — Older age of onset: New headaches after age 50 broaden differential diagnoses. I consider giant cell arteritis, especially with jaw claudication, scalp tenderness, and weight loss—vision is at risk without prompt steroids.
• P — Pattern change or precipitants:
  • Pattern change: A shift from predictable menstrual migraine to daily headache triggers imaging.
  • Precipitants: Headache only with exertion, coughing, sneezing, or Valsalva raises concern for space-occupying lesions or Chiari malformation.
  • Positional changes: Severe orthostatic headache relieved by lying down suggests spontaneous intracranial hypotension.
  • Sexual activity-induced headaches: Often benign but can mirror Valsalva physiology and need careful evaluation initially.

Using SNOOP rigorously helps us do no harm by identifying patients who need urgent workup before we proceed.

Diagnostic Criteria: Migraine Without Aura (ICHD-3)

Once secondary causes are excluded, I apply ICHD-3 criteria for migraine without aura:

• At least five attacks lasting 4–72 hours (untreated or unsuccessfully treated).
• At least two of:
  • Unilateral location
  • Pulsating quality
  • Moderate to severe intensity
  • Aggravation by routine physical activity
• At least one of:
  • Nausea and/or vomiting
  • Photophobia and phonophobia

These criteria are flexible. A bilateral, pressure-like, moderate-intensity headache that worsens with movement plus nausea can still be migraine. Listen carefully for associated symptoms and activity aggravation—migraine can masquerade.

Quick Screening: The ID Migraine Tool

The ID Migraine™ screener simplifies detection in busy settings. Using PIN:

• P — Photophobia: Is light unusually bothersome during headaches?
• I — Impairment: In the last three months, have headaches limited your ability to work or function for at least one day?
• N — Nausea: Do you feel nauseated during headaches?

Two “yes” answers yield about 93% positive predictive value for migraine once red flags are excluded (Headache Classification Committee of the International Headache Society, 2018).

Migraine vs. Tension-Type Headache: The Practical Differentiator

Ask one key question: “Does routine physical activity make your headache worse?“

• Yes strongly favors migraine.
• No suggests tension-type headache.

Patients with tension-type headache often feel better after moving or stretching. Migraine patients typically avoid activity to prevent worsening pain.

The Migraine Timeline: Understanding the Five Phases

Migraine unfolds in distinct phases. Recognizing them improves diagnosis and treatment timing.

• Interictal phase: The pain-free baseline between attacks. Preventive strategies aim to extend this phase.
• Prodrome (hours to days pre-headache): About 70% experience:
  • Light and sound sensitivity
  • Fatigue and yawning
  • Difficulty concentrating, brain fog, word-finding problems
  • Mood changes (irritability, euphoria)
  • Food cravings
  • Dizziness
  • Neck stiffness (often mistaken as the cause; it is frequently the first expression of the migraine brain)
• Aura (≈30%): Transient, reversible neurological symptoms lasting <60 minutes:
  • Visual aura (positive phenomena: shimmering lights, zig-zags) from cortical spreading depression across the visual cortex
  • Sensory aura (marching tingling)
  • Language aura (transient aphasia)
• Headache: 4–72 hours of moderate to severe, often pulsating pain plus nausea, photophobia, phonophobia.
• Postdrome (“migraine hangover“, 24–48 hours): Exhaustion, cognitive “slowness,” scalp tenderness (allodynia), and diffuse muscle aches.

Patients may lose three to four days per attack—timely, mechanism-matched interventions are critical.

Pathophysiology: Migraine as a Disorder of Sensory Processing

Modern research reframes migraine: not just vascular, but primarily neurological, with secondary vascular changes. Its genetics, central circuitry, and neurochemical environment create a brain primed to overreact (Goadsby et al., 2017).

Central Generators: Hypothalamus, Limbic System, and Brainstem

• Hypothalamus: The master regulator of circadian rhythms, appetite, stress, and endocrine outputs. It activates before pain begins; its dysregulation drives prodrome (yawning, cravings, mood shifts). Hypothalamic hypersensitivity explains why changes in sleep, meals, stress, or barometric pressure trigger attacks.
• Limbic system: Dense connectivity with hypothalamus links emotional tone to migraine—mood shifts and anxiety are integral, not incidental.
• Trigeminal nucleus caudalis (TNC): Brainstem hub receiving inputs from trigeminal afferents (face/scalp/meninges) and upper cervical roots. In migraine, TNC becomes sensitized, lowering the threshold for pain transmission.

Peripheral Drivers: Trigeminovascular System and CGRP

The trigeminal nerve (especially the ophthalmic division, V1) innervates the dura mater and meningeal vessels. Activation releases neuropeptides, notably CGRP—a potent vasodilator and pain transmitter.
Key findings:

• CGRP levels rise in the jugular vein during attacks; they normalize interictally (Goadsby, Edvinsson, & Ekman, 1990).
• Injecting CGRP into migraineurs can trigger attacks.
• Blocking CGRP or its receptor can effectively treat and prevent migraine.

CGRP drives:

• Vasodilation of meningeal vessels (contributing to throbbing)
• Neurogenic inflammation via mast cell degranulation (histamine, prostaglandins, cytokines)
• Pain signal propagation and sensitization in trigeminal circuits

Central Sensitization and Allodynia: Turning Up the Gain

Sustained nociceptive input “rewires” central circuits, creating central sensitization:

• Patients experience allodynia (scalp tenderness, pain with glasses or collars)
• The system becomes hyperexcitable—non-painful stimuli hurt; mild pain becomes severe.

This phenomenon explains why early treatment is crucial—once sensitization is established during an attack, suppression is harder, and the risk of transformation to chronic migraine rises.

Why Integrative Chiropractic Care Fits in Migraine Treatment

Chiropractic care is not a cure-all for a central neurological disorder, but it plays a strategic, physiologically grounded role. It reduces cervical nociceptive traffic feeding into the brainstem and improves sensorimotor control—effectively decreasing a key afferent amplifier.

The Trigeminocervical Complex: Convergence in the Brainstem

The TNC receives input from:

• Trigeminal afferents (CN V, especially V1)
• Upper cervical roots (C1–C3)

This convergence means cervical dysfunction (joint restriction, muscle hypertonicity, dural tension) can prime or amplify brainstem sensitization. Conversely, restoring cervical segmental motion and soft-tissue balance reduces peripheral drive into TNC, lowering the probability and intensity of attacks.

My Clinical Approach: Structural, Neurological, and Autonomic Targets

• Thorough cervical exam: Palpation for joint restrictions, range-of-motion testing, evaluation of suboccipital and SCM tension, assessment of dural mechanosensitivity.
• Specific chiropractic adjustments:
  • Gentle, targeted mobilizations or high-velocity low-amplitude (HVLA) adjustments focused on C0–C3
  • Goals:
    • Restore biomechanics in restricted segments
    • Reduce nociceptive input from dysfunctional joints and fascia
    • Improve proprioception and sensorimotor feedback to the central nervous system
    • Decrease muscle hypertonicity via reflex pathways
• Soft-tissue therapies:
  • Myofascial release and trigger point therapy for suboccipital triangle, SCM, upper trapezius, levator scapulae
  • Duraplasty-inspired gentle cranial and fascial mobilizations to reduce pericranial mechanosensitivity
• Neuromuscular re-education:
  • Deep cervical flexor activation, scapular stabilization, proprioceptive drills
  • Vestibulo-oculomotor rehabilitation when motion sensitivity or post-concussive patterns exist
  • Goal: recalibrate sensorimotor control to decrease autonomic arousal and re-injury cycles
• Autonomic balancing:
  • Breathwork, heart rate variability (HRV)-guided pacing, vagal-tone practices
  • Shift from sympathetic dominance to parasympathetic recovery, raising pain thresholds

Why This Works: Direct Links to Migraine Physiology

• Cervical afferents are not”noise”—they converge in the same brainstem hub that processes trigeminal pain. When cervical dysfunction is active, the TNC is more likely to amplify. Correcting cervical inputs reduces “afferent load,” helping pharmacotherapy work better and lowering the risk of chronic sensitization.
• Improved posture and segmental control reduce repetitive strain on meningeal and pericranial tissues, lowering mechanotransduction that can perpetuate migraine pathways.

Functional Medicine: Stabilizing the Terrain That Lowers the Migraine Threshold

Migraine biology is exquisitely sensitive to metabolic and hormonal fluctuations. Functional medicine interventions “raise the threshold” and reduce triggers.

Key Areas of Investigation and Support

• Sleep architecture restoration:
  • Treat sleep apnea, standardize circadian timing, optimize light exposure and temperature
  • Stabilized sleep reduces hypothalamic dysregulation—a central migraine generator
• Glycemic stability and nutrition:
  • Regular protein-anchored meals to steady glucose and insulin
  • Anti-inflammatory dietary patterns rich in polyphenols and omega-3s; reduce processed foods and alcohol
  • Targeted nutraceuticals:
    • Magnesium (glycinate or threonate) for neuronal excitability
    • Riboflavin (B2) for mitochondrial support
    • Coenzyme Q10 for energy metabolism
• These have supportive evidence in migraine prevention (Ashina et al., 2021)
• Hormonal rhythm support:
  • For menstrual migraine, longer half-life triptans (naratriptan, frovatriptan) peri-menses; magnesium uptitration; NSAID bridging (naproxen)
  • Saliva or urine (DUTCH) testing for nuanced patterns when clinically indicated
• Iron and thyroid screening:
  • Correct iron deficiency and thyroid dysfunction; both can contribute to fatigue, sleep disruption, and neurological instability
• Hydration and electrolytes:
  • Adequate hydration; balanced electrolytes to support neuronal function

Why This Matters: Mechanistic Rationale

Stabilizing sleep, glucose, and hormones reduces hypothalamic triggers and limbic amplification.
Micronutrients support mitochondria—critical for cortical neurons prone to cortical spreading depression (aura physiology).
Anti-inflammatory strategies reduce systemic cytokine tone, lowering central excitability and pain facilitation.

Pharmacological Treatment: Acute and Preventive Strategies

Our pharmacologic approach is divided into acute (stopping attacks early) and preventive (reducing frequency, severity, and duration). Timing and mechanism matching are crucial.

Acute Treatment: Treat Early to Prevent Central Sensitization

• Goals of acute therapy:
  • Rapid pain freedom within two hours
  • Relief of nausea, photophobia, phonophobia
  • Functional recovery
  • Minimal side effects
  • Sustained relief without recurrence
• Toolkit stratification:
  • Mild pain: NSAIDs (naproxen, ibuprofen) or acetaminophen; screen for GI, renal, hypertension, and anticoagulation risks; emphasize early dosing
  • Moderate attacks: Migraine-specific agents:
    • Triptans (sumatriptan, rizatriptan, eletriptan, naratriptan, frovatriptan)
    • Ergot derivatives (DHE formulations)
    • Ditans (lasmiditan) for vascular contraindications to triptans
    • Gepants (ubrogepant, rimegepant, zavegepant), especially when triptans are intolerable or contraindicated
  • Severe attacks/high-risk phenotype: Combine a migraine-specific agent with a dopamine antagonist antiemetic (metoclopramide, chlorpromazine, promethazine); use non-oral routes (subcutaneous or nasal) when gastric stasis limits absorption; consider DHE autoinjector for rapid action

Mechanisms You Can Leverage

• Triptans (5-HT1B/1D agonists):
  • Presynaptic inhibition of CGRP release
  • Vasoconstriction of meningeal vessels via 5-HT1B
  • Contraindications: ischemic heart disease, cerebrovascular disease, peripheral vascular disease, uncontrolled hypertension
  • Clinical pearl: If one triptan fails, another may succeed; longer half-life agents help with menstrual migraines
• Ditans (5-HT1F agonist, lasmiditan):
  • Central stabilization of migraine generators without vasoconstriction
  • Benefits for patients with vascular risk
  • Limitations: dizziness, somnolence; do not drive for eight hours
• Gepants (CGRP receptor antagonists: ubrogepant, rimegepant, zavegepant):
  • Postsynaptic blockade of CGRP receptor; no vasoconstriction
  • Advantages: reduced risk of medication overuse headache; not controlled substances
  • CYP3A4 metabolism: caution with inducers (e.g., topiramate) and inhibitors (e.g., verapamil)
• Postmarketing signals: rare hypertension and Raynaud’s phenomenon; monitor blood pressure and counsel on Raynaud’s symptoms (Ashina et al., 2021)

Practical Pearls

• Non-oral routes bypass delayed gastric emptying and vomiting during attacks.
• Pair antiemetics with migraine-specific agents to improve analgesia and nausea control.
• For recurrences after initial relief:
  • Add an NSAID or a dopamine antagonist
  • Switch to longer half-life triptans (naratriptan, frovatriptan)
• Medication overuse education:
  • Triptans/ergots/opioids/butalbital combos: limit to ≤10 days/month
  • Simple analgesics: limit to ≤15 days/month
  • Overuse sensitizes central circuits and promotes chronification (Buse et al., 2019)

Preventive Treatment: Choosing the Right Strategy

• Consider prevention when:
  • Migraines occur 2–4 times/month with significant impact
  • 4–6 times/month regardless of intensity
  • Acute meds are overused, ineffective, or poorly tolerated
  • Attacks interfere substantially with function
  • Patient prefers preventive therapy
  • Phenotype suggests risk of chronification

Legacy Preventive Options

• Antihypertensives: Beta-blockers (propranolol, metoprolol), calcium channel blockers (verapamil), angiotensin receptor blocker candesartan (supported by Grade A evidence)
• Antidepressants: Tricyclics (amitriptyline, nortriptyline), SNRIs (venlafaxine)
• Anticonvulsants: Topiramate, valproic acid (avoid in women of childbearing potential due to teratogenicity)

Tailor choice to comorbidities:

• Migraine + hypertension: beta-blocker or ARB
• Migraine + depression/anxiety: TCA or SNRI
• Migraine + insomnia: bedtime TCA
• Migraine + weight concerns: topiramate may assist weight loss, but monitor cognition

CGRP-Targeted Preventives: Monoclonal Antibodies and Gepants

• Monoclonal antibodies:
  • Ligand-targeting: Eptinezumab (Vyepti, IV quarterly), Fremanezumab (Ajovy, SQ monthly or quarterly), Galcanezumab (Emgality, SQ monthly)
  • Receptor-targeting: Erenumab (Aimovig, SQ monthly)
  • Mechanism: neutralize CGRP ligand or block receptor; reduce meningeal vasodilation and neurogenic inflammation; dampen trigeminovascular signaling
  • Advantages: migraine-specific, favorable tolerability, minimal CNS side effects; metabolized via proteolysis, limiting drug-drug interactions
  • Considerations: injection site reactions; constipation and hypertension signals notably with erenumab; counsel and monitor
• Preventive gepants:
  • Rimegepant (Nurtec ODT): every other day for prevention; also effective acutely
  • Atogepant (Qulipta): once daily (10, 30, 60 mg; 60 mg for chronic migraine)
  • CYP3A4 interactions: adjust dosing with inducers/inhibitors
  • Side effects: nausea, constipation, somnolence; mild appetite changes

OnabotulinumtoxinA (Botox) for Chronic Migraine

• Indication: chronic migraine (≥15 headache days/month)
• Mechanism: cleaves SNAP-25, blocking SNARE-mediated exocytosis of CGRP and other transmitters at peripheral trigeminal afferents; reduces peripheral sensitization and indirectly central sensitization
• PREEMPT protocol: 31 injections across pericranial and cervical regions (corrugator, procerus, frontalis, temporalis, occipitalis, cervical paraspinals, trapezius)
  • Synergy with chiropractic and rehab:
  • Correct cervical myofascial dysfunction to reduce brainstem sensitization and enhance response durability (Dodick, 2018; Diener et al., 2010)

Integrative Clinical Pathway: Step-by-Step in Our Clinic

• Comprehensive evaluation:
  • Detailed timeline, phenotype, triggers, family history, and SNOOP screen
  • Cervical and cranial biomechanics; myofascial mapping; oculomotor and vestibular screening
  • Cardiometabolic, endocrine, and sleep assessment
  • Medication inventory and CYP3A4 interaction screen
• Shared decision-making on goals:
  • Pain freedom targets, functional restoration, monthly med use limits
• Acute plan by severity tier:
  • Mild: NSAID/acetaminophen with risk checks
  • Moderate: migraine-specific agent; non-oral routes when needed
  • Severe: add dopamine antagonist; consider DHE autoinjector; ensure antiemetic route bypasses gastric stasis
• Prevention plan when indicated:
  • Legacy preventives matched to comorbidities
  • CGRP-targeted agents (mAbs or gepants)
  • OnabotulinumtoxinA for chronic migraine and central sensitization phenotypes
• Integrative chiropractic and rehab:
  • Segmental correction, cranial and dural mobilization, soft-tissue normalization
  • Neuromotor retraining, graded exercise, vestibulo-oculomotor work
• Functional medicine supports:
  • Sleep optimization, nutrition, micronutrients, hormone-aware strategies
  • Hydration and electrolyte balance
• Monitoring and iteration:
  • Headache diaries; monthly check-ins; side-effect tracking; HRV measures
  • Validated scales: MIDAS, HIT-6, PGIC
  • Adjust protocols every 4–12 weeks based on response

Clinical Scenarios: Decision Reasoning in Practice

• Vascular risks with triptan history and new refractory hypertension:
  • Switch to lasmiditan or a gepant; counsel on driving restrictions for lasmiditan and monitor BP for gepants
• Menstrual migraine lasting up to 72 hours:
  • Use longer half-life triptans (naratriptan, frovatriptan); consider peri-menses naproxen bridging; reinforce sleep and magnesium uptitration
• Frequent nausea/vomiting during attacks:
  • Prefer non-oral triptan or DHE; add metoclopramide/promethazine; coach on early dosing at aura or prodrome
• Nearing medication overuse thresholds:
  • Initiate prevention (e.g., atogepant or rimegepant); integrate chiropractic and functional measures to reduce acute reliance
• Chronic migraine with neck dysfunction:
  • Combine onabotulinumtoxinA with cervical biomechanics correction and neuromuscular rehab to reduce brainstem sensitization

Safety, Drug Interactions, and Postmarketing Signals

Under Dr. Cardenas’ internal medicine oversight, we screen and monitor:

• Vascular disease, hypertension, stroke history:
  • Avoid vasoconstrictive triptans; consider lasmiditan or gepants
  • Monitor blood pressure, especially with gepants and erenumab
• Renal and hepatic function:
  • Adjust NSAID, triptan, and gepant selection/dosing
• CYP3A4 interactions:
  • Topiramate (inducer) may lower gepant levels; verapamil (inhibitor) may elevate them
• Raynaud’s phenomenon:
  • Educate patients on symptoms (digits turning white/blue with cold) and report promptly
• Sleep disorders, anxiety/depression:
  • Choose preventives aligning with comorbid needs while minimizing cognitive/metabolic side effects

This vigilance ensures efficacy with systemic safety, and our integrative supports help reduce medication burden over time.

Personal Injury and Post-Traumatic Migraine: Addressing Cervical and Autonomic Sequelae

After whiplash or concussion:

• Facet injury, ligament strain, and vestibular dysfunction increase trigeminal convergence and sensory hypersensitivity.
• Early gentle mobilization, soft-tissue care, and vestibulo-oculomotor rehab reduce central sensitization.
• Graded return to activity, autonomic regulation, and sleep restoration prevent chronification.

Rationale:

• Post-traumatic dysautonomia and cervical nociception can entrench central sensitization unless addressed early with multimodal care.

The Physiology Behind Our Integrative Strategy

Every intervention maps to migraine biology:

• Trigeminovascular system: nociceptor activation, CGRP release, meningeal vasodilation, and neurogenic inflammation
• Central sensitization: amplified brainstem excitability and thalamocortical dysrhythmia
• Cervical-trigeminal convergence: upper cervical afferents feed TNC alongside trigeminal inputs
• Autonomic imbalance: sympathetic dominance lowers pain thresholds and worsens photophobia/phonophobia
• Metabolic stress: mitochondrial inefficiency and glucose variability heighten susceptibility to cortical spreading depression

Acute meds target nociceptive signaling; preventives modulate neurochemical cascades; chiropractic corrects peripheral drivers; functional medicine stabilizes terrain; rehabilitation recalibrates sensorimotor control and autonomic balance.

Our Collaborative Model in Action

• Dr. Maria Guadalupe Cardenas, MD
  • Medical Director and Collaborative Physician
  • NPI #1164426749; Texas MD License #J2933
  • Oversees medical diagnostics, comorbidity management, and pharmacotherapy safety
• Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST
  • Leads integrative chiropractic, rehabilitation, and functional medicine
  • Coordinates personalized protocols and monitors outcomes across disciplines

This multidisciplinary model—an MD providing medical direction alongside a chiropractor—is standard in integrative and injury care clinics, and it is highly effective for migraine.
Stay connected:

• https://chiromed.com/
• https://www.linkedin.com/in/dralexjimenez/

Evidence-Based Highlights: What the Research Shows

• Pathophysiology: Migraine as a sensory processing disorder with hypothalamic and brainstem generators; trigeminovascular activation; CGRP’s central role (Goadsby et al., 2017).
• CGRP findings: Elevated CGRP during attacks; CGRP infusion triggers migraine; CGRP blockade treats and prevents attacks (Goadsby, Edvinsson, & Ekman, 1990; Dodick, 2018).
• CGRP-targeted therapies: Monoclonal antibodies (ligand or receptor) and gepants offer migraine-specific options with favorable tolerability (Urits et al., 2020; Ashina et al., 2021).
• Acute neuromodulation: Single-pulse transcranial magnetic stimulation for migraine with aura shows evidence of benefit (Lipton et al., 2010).
• OnabotulinumtoxinA: PREEMPT trials established efficacy for chronic migraine by presynaptic blockade of neuropeptide release (Diener et al., 2010; Dodick, 2018).
• Medication overuse: Overuse drives central sensitization and chronic transformation; prevention is key (Buse et al., 2019).

Key Takeaways for Patients and Clinicians

• Think migraine first when activity worsens head pain and associated symptoms are present.
• Treat early with a stratified acute toolkit matched to attack phenotype and severity.
• Prevent when appropriate, especially at ≥4 migraine days/month, high disability, or acute overuse.
• Leverage CGRP-targeted therapies and onabotulinumtoxinA thoughtfully; they are migraine-specific and often well tolerated.
• Correct cervical and cranial biomechanical drivers; convergence at the brainstem means cervical inputs matter.
• Stabilize sleep, metabolic, and hormonal rhythms to raise the migraine threshold.
• Collaborate across disciplines—internal medicine, chiropractic, rehabilitation, and functional medicine—for faster, more durable recovery.

References

• Ashina, M., et al. (2021). CGRP in migraine: From pathophysiology to therapy. Headache: The Journal of Head and Face Pain.
• Buse, D. C., et al. (2019). Medication-overuse headache: Mechanisms and management. Headache.
• Diener, H. C., Dodick, D. W., Aurora, S. K., Turkel, C. C., DeGryse, R. E., Lipton, R. B., … & Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia, 30(7), 804–814.
• Dodick, D. W. (2018). CGRP-targeted monoclonal antibody therapy for migraine prevention. The Lancet, 392(10161), 2261–2263.
• Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology, 28(2), 183–187.
• Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017). Pathophysiology of migraine: A disorder of sensory processing. Physiological Reviews, 97(2), 553–622.
• Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1–211.
• Lipton, R. B., Dodick, D. W., Silberstein, S. D., Saper, J. R., Aurora, S. K., Goadsby, P. J., … & Tepper, S. J. (2010). Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomized, double-masked, parallel-group, sham-controlled trial. The Lancet Neurology, 9(4), 373–380.
• Urits, I., Clark, G., An, D., Wesp, B., Zhou, R., Amgalan, A., … & Viswanath, O. (2020). An evidence-based review of fremanezumab for the treatment of migraine. Pain and Therapy, 9(2), 593–605.
• American Headache Society. (2024). Consensus statements on preventive and acute treatment strategies in migraine.
• National Headache Foundation. (2022). Position statement on individualized preventive therapy in migraine.
• Goadsby, P. J., et al. (2019). Rimegepant for acute and preventive treatment of migraine. New England Journal of Medicine.
• Lipton, R. B., et al. (2020). Ubrogepant in acute migraine: Efficacy and safety. JAMA.
• Ailani, J., et al. (2021). Atogepant for prevention of migraine. The Lancet Neurology.
• Silberstein, S. D., et al. (2018–2023). Monoclonal antibodies targeting CGRP or its receptor in migraine prevention. NEJM, The Lancet, Cephalalgia.
• Charles, A. (2018). The pathophysiology of migraine: Implications for clinical management. The Lancet Neurology.
• Clinical observations and integrative protocols by Dr. Alexander Jimenez, DC, APRN, FNP-BC. Injury Medical Clinic PA insights; Professional profile.

SEO tags: migraine, migraine treatment, migraine pathophysiology, CGRP, CGRP antagonists, monoclonal antibodies, gepants, triptans, ditans, onabotulinumtoxinA, Botox for migraine, dihydroergotamine, ID Migraine, SNOOP mnemonic, central sensitization, trigeminovascular system, trigeminal nucleus caudalis, hypothalamus, limbic system, chiropractic care, integrative chiropractic, cervical-trigeminal convergence, functional medicine, sleep optimization, nutrition, magnesium, riboflavin, CoQ10, vestibulo-oculomotor rehab, autonomic balancing, medication overuse headache, American Headache Society, El Paso TX, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic